Protara Therapeutics, Inc. announced on March 19, 2025, an encore presentation of data from its THRIVE-1 prospective, observational study. The results, evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS), were featured at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2025 Nutrition Science & Practice Conference.
The THRIVE-1 study demonstrated that 78% of patients dependent on PS were choline deficient. Of these choline-deficient participants, 63% exhibited liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury. These findings underscore the significant unmet need for IV choline replacement therapy in this patient population.
Protara reiterated its commitment to bringing the first approved IV formulation of choline to the PS community. The company plans to initiate its registrational THRIVE-3 clinical trial, a seamless Phase 2b/3 study, in the first half of 2025, further advancing its IV Choline Chloride program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.